176 related articles for article (PubMed ID: 35077154)
1. Intervention with the Bone-Associated Tumor Vicious Cycle through Dual-Protein Therapeutics for Treatment of Skeletal-Related Events and Bone Metastases.
Niu Y; Yang H; Yu Z; Gao C; Ji S; Yan J; Han L; Huo Q; Xu M; Liu Y
ACS Nano; 2022 Feb; 16(2):2209-2223. PubMed ID: 35077154
[TBL] [Abstract][Full Text] [Related]
2. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis.
Li B; Wang P; Jiao J; Wei H; Xu W; Zhou P
Front Immunol; 2022; 13():824117. PubMed ID: 35386705
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
4. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
5. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
6. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
8. Understanding and targeting osteoclastic activity in prostate cancer bone metastases.
Sottnik JL; Keller ET
Curr Mol Med; 2013 May; 13(4):626-39. PubMed ID: 23061677
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
10. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.
Nakajima K; Kho DH; Yanagawa T; Harazono Y; Hogan V; Chen W; Ali-Fehmi R; Mehra R; Raz A
Cancer Res; 2016 Mar; 76(6):1391-402. PubMed ID: 26837763
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacologic Therapy for Bone Metastases-Current Strategies and Future Directions].
Suzuki T; Sekine I
Gan To Kagaku Ryoho; 2023 Mar; 50(3):299-303. PubMed ID: 36927895
[TBL] [Abstract][Full Text] [Related]
13. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
14. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
Gupta A; Cao W; Chellaiah MA
Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
[TBL] [Abstract][Full Text] [Related]
15. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.
Lynch CC
Bone; 2011 Jan; 48(1):44-53. PubMed ID: 20601294
[TBL] [Abstract][Full Text] [Related]
17. CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.
Chen PC; Cheng HC; Tang CH
Carcinogenesis; 2013 Jul; 34(7):1669-79. PubMed ID: 23536580
[TBL] [Abstract][Full Text] [Related]
18. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Lipton A; Goessl C
Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
